CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Moderate Buy” by Brokerages

CG Oncology, Inc. (NASDAQ:CGON) has been given an average rating of “Moderate Buy” by the fourteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $69.00.

CGON has been the subject of a number of research analyst reports. Truist Financial raised their target price on CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Piper Sandler raised their price objective on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $82.00 target price on shares of CG Oncology in a research note on Monday, January 12th. Royal Bank Of Canada increased their target price on shares of CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Finally, Morgan Stanley set a $93.00 price target on shares of CG Oncology in a research note on Friday, January 9th.

Insider Transactions at CG Oncology

In related news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. purchased a new stake in shares of CG Oncology in the 4th quarter valued at approximately $27,000. Strengthening Families & Communities LLC purchased a new stake in shares of CG Oncology during the 3rd quarter worth $40,000. Comerica Bank grew its stake in shares of CG Oncology by 100.4% during the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after purchasing an additional 515 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in CG Oncology by 15.2% in the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock valued at $85,000 after buying an additional 433 shares during the last quarter. Finally, Picton Mahoney Asset Management purchased a new position in CG Oncology in the fourth quarter valued at $118,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

CG Oncology Stock Performance

NASDAQ:CGON opened at $63.84 on Wednesday. CG Oncology has a fifty-two week low of $14.80 and a fifty-two week high of $69.35. The company has a 50 day moving average price of $57.33 and a 200 day moving average price of $46.65. The stock has a market capitalization of $5.39 billion, a P/E ratio of -30.84 and a beta of 1.18.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The firm had revenue of $2.32 million for the quarter. Research analysts forecast that CG Oncology will post -1.31 earnings per share for the current fiscal year.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.